Seattle Genetics to Host Research and Development Day on December 12, 2007
Posted on: Wednesday, 5 December 2007, 09:01 CST
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that company management will host a research and development day for the financial community on December 12, 2007 beginning at 9:15 a.m. Eastern Time. The event will be held at the Grand Hyatt Hotel in New York City.
The meeting will include a review of recent clinical data reported on SGN-33 and SGN-35 and a discussion of the company's SGN-40 clinical development program in collaboration with Genentech, and will feature presentations by clinical investigators. Scheduled speakers include:
Ranjana Advani, M.D. -- Associate Professor of Medicine/Oncology at Stanford University Medical Center
Andres Forero-Torres, M.D. -- Associate Professor, Division of Hematology/Oncology, Comprehensive Cancer Center at University of Alabama at Birmingham
Joseph Jurcic, M.D. -- Acting Chief, Leukemia Service at Memorial Sloan-Kettering Cancer Center
Azra Raza, M.D. -- Professor of Medicine and Director, MDS Program at St. Vincent's Comprehensive Cancer Center
A webcast of the meeting will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section.
About Seattle Genetics
Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including lymphoma, multiple myeloma, leukemia and solid tumors. The company has an exclusive worldwide collaboration agreement with Genentech to develop and commercialize SGN-40. Seattle Genetics also has three other proprietary programs in ongoing clinical trials: SGN-33, SGN-35 and SGN-30. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune, as well as an ADC co-development agreement with Agensys. More information can be found at www.seattlegenetics.com.
Source: Business Wire
Related Articles
- NCI Renews Mayo Clinic Cancer Center Support Grant, Extends Comprehensive Status
- Seattle Genetics Achieves Milestone in Antibody-Drug Collaboration
- Seattle Genetics Initiates Phase Ib Myeloma Trial
- Seattle Genetics to Receive Milestone Payment From Genentech
- Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
- Seattle Genetics Initiates Phase II Clinical Trial of SGN-40 for the Treatment of Non-Hodgkin's Lymphoma
- Seattle Genetics Announces Advancements in Development Programs at American Society of Hematology Meeting
- Seattle Genetics Reports Positive Phase I Clinical Trial Results With SGN-40 in Non-Hodgkin's Lymphoma and Multiple Myeloma at ASH
- Seattle Genetics Initiates Phase I Clinical Trial of SGN-35
- National Association of Cancer Center Development Officers Selects Grizzard As Agency of Record
 |
 |
User Comments (0)
RSS Feeds